[HTML][HTML] Ofatumumab versus teriflunomide in multiple sclerosis
Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Ofatumumab versus Teriflunomide in Multiple Sclerosis
SL Hauser, A Bar-Or, JA Cohen, G Comi… - NEW ENGLAND …, 2020 - iris.uniroma1.it
BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
[HTML][HTML] Ofatumumab versus Teriflunomide in Multiple Sclerosis.
SL Hauser, A Bar-Or, JA Cohen, G Comi… - The New England …, 2020 - folia.unifr.ch
Ofatumumab versus Teriflunomide in Multiple Sclerosis. SONAR logo Log in Sign up EN
English Français Deutsch Italiano Back Ofatumumab versus Teriflunomide in Multiple Sclerosis …
English Français Deutsch Italiano Back Ofatumumab versus Teriflunomide in Multiple Sclerosis …
[PDF][PDF] Ofatumumab versus Teriflunomide in Multiple Sclerosis
SL Hauser, A Bar-Or, JA Cohen, G Comi, J Correale… - N Engl J Med, 2020 - core.ac.uk
BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Ofatumumab versus Teriflunomide in Multiple Sclerosis
S Hauser, A Bar-Or, J Cohen, G Comi… - … England Journal of …, 2020 - hal.umontpellier.fr
Background: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
[引用][C] Ofatumumab versus Teriflunomide in Multiple Sclerosis
SL Hauser, A Bar-Or, JA Cohen, G Comi… - New England Journal …, 2020 - cir.nii.ac.jp
Ofatumumab versus Teriflunomide in Multiple Sclerosis | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[PDF][PDF] Ofatumumab versus Teriflunomide in Multiple Sclerosis
SL Hauser, A Bar-Or, JA Cohen, G Comi… - N Engl J …, 2020 - researchgate.net
BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Ofatumumab versus Teriflunomide in Multiple Sclerosis
SL Hauser, A Bar-Or, JA Cohen… - The New England …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
SL Hauser, A Bar-Or, JA Cohen, G Comi… - The New England …, 2020 - portalrecerca.uab.cat
BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Ofatumumab versus teriflunomide in multiple sclerosis
SL Hauser, A Bar-Or, JA Cohen… - The New England …, 2020 - repository.uantwerpen.be
Background: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …